TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Form 10-Q — Nov 3, 2026

$TEVAForm 10-QFiled Nov 3, 2026, 4:06 PM ET0000818686-26-000006Original filing

Teva's Q3 2026 net revenues were $4,395 million, down roughly 2% from $4,480 million a year earlier, with U.S. segment revenue slipping to $1,870 million from $2,090 million. Quarterly net income fell to $234 million ($0.20 diluted EPS) from $434 million ($0.37) in Q3 2025, weighed down by a $224 million loss on early extinguishment of debt, $202 million in legal settlements and loss contingencies, and $264 million of impairments and restructuring charges. Nine-month net income was just $27 million versus $937 million a year ago.

Key figures

Eps: Q3 2026 basic/diluted EPS $0.20 (vs $0.38/$0.37 in Q3 2025); nine-month EPS $0.02
Revenue: Q3 2026: $4,395M (vs $4,480M in Q3 2025); nine months 2026: $12,519M
Net Income: Q3 2026: $234M attributable to Teva $233M (vs $434M/$433M); nine months 2026: $27M (vs $937M)
Total Debt: Total senior notes $16,786M, short-term debt $4,038M, total senior notes and loans (net) $12,680M long-term plus $4,038M current
Revenue Yoy: Q3 2026 revenue declined ~1.9% YoY
Total Assets: $40,042M
Cash Position: $4,085M as of September 30, 2026
Emalex acquisition: ~$700M cash paid June 2026 plus up to $200M and $125M milestones; NDA for ecopipam (EBS-101) accepted with FDA Priority Review
Shares outstanding: 1,166,826,784 ordinary shares as of September 30, 2026
Impairments q3 2026: $24M intangible impairments; $264M other assets impairments/restructuring
Operating income q3 2026: $714M (vs $882M in Q3 2025)
Bioxcel asset acquisition: $58M upfront plus up to $68M contingent payments, completed October 27, 2026
Legal settlements q3 2026: $202M in legal settlements and loss contingencies
Revolving credit facility: $1.8B unsecured syndicated RCF, matures April 2028, no amounts outstanding
September 2026 refinancing: Issued ~$4.7B equivalent of senior notes ($1,200M 5.25% due 2032; EUR1,000M 4.25% due 2033; $1,000M 5.50% due 2034; EUR500M 4.63% due 2036; $1,000M 5.75% due 2037); early redemption of ~$4.3B of 2027-2031 notes
Loss on debt extinguishment: $224M recorded in financial expenses, net

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.